Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 11/20 | 0.43 |
| ▸ | MGAM | O43451 | 10/20 | 0.43 |
| ▸ | AMY1A | P0DUB6 | 10/20 | 0.43 |
| ▸ | SI | P14410 | 10/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 10/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.40 |
| ▸ | F12 | P00748 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3893181 | 0.94 | DGAT1 (0.57) | DGAT1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL1971917 | 0.91 | DGAT1 (0.51) | DGAT1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL21904738 | 0.91 | DGAT1 (0.51) | DGAT1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL21904737 | 0.89 | DGAT1 (0.49) | DGAT1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL2732055 | 0.81 | DGAT1 (0.49) | DGAT1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL29031460 | 0.81 | DGAT1 (0.49) | DGAT1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL20591983 | 0.80 | TUBB4A (0.41) | — | |
| SCHEMBL29369659 | 0.80 | TUBB4A (0.41) | — | |
| SCHEMBL29538691 | 0.80 | TUBB4A (0.41) | DGAT1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL29475401 | 0.79 | PKM (0.41) | MAPTKDM4EHTTKCNMA1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250134812-A1 | SYNTHETIC GLYCOLIPIDS AND GLYCOLIPOSOME COMPOSITIONS : SUITABLE FOR CARGO DELIVERY TO THE CENTRAL NERVOUS SYSTEM | KORANEX CAPITAL (CA) | 2025-05-01 | — | — | US | claimed |
| US-20240360147-A1 | Process for Synthesizing Naphthyridine Derivatives and Intermediates Thereof | AMGEN INC. | 2024-10-31 | — | — | US | claimed |
| EP-4396170-A1 | PROCESS FOR SYNTHESIZING NAPHTHYRIDINE DERIVATIVES AND INTERMEDIATES THEREOF | Amgen Inc. (US) | 2024-07-10 | — | — | EP | claimed |
| WO-2023141693-A1 | SYNTHETIC GLYCOLIPIDS AND GLYCOLIPOSOME COMPOSITIONS SUITABLE FOR CARGO DELIVERY TO THE CENTRAL NERVOUS SYSTEM | KORANEX CAPITAL (CA) | 2023-08-03 | — | — | WO | claimed |
| WO-2023141692-A1 | SYNTHETIC GLYCOLIPIDS AND GLYCOLIPOSOME COMPOSITIONS SUITABLE FOR CARGO DELIVERY TO THE CENTRAL NERVOUS SYSTEM | KORANEX CAPITAL (CA) | 2023-08-03 | — | — | WO | claimed |
| WO-2023034786-A1 | PROCESS FOR SYNTHESIZING NAPHTHYRIDINE DERIVATIVES AND INTERMEDIATES THEREOF | AMGEN INC. (US) | 2023-03-09 | — | — | WO | claimed |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2026-05-21 | — | — | US | disclosed |
| US-12577236-B2 | Processes for preparation of Tezacaftor | LAURUS LABS LIMITED (IN) | 2026-03-17 | — | — | US | disclosed |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | INSTITUT CURIE (FR) | 2026-01-20 | — | — | US | disclosed |
| US-20250368657-A1 | METHODS FOR INHIBITING FASCIN | NOVITA PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-12365649-B2 | Process for the preparation of brivaracetam | ALIVUS LIFE SCIENCES LIMITED (IN) | 2025-07-22 | — | — | US | disclosed |
| US-12297226-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20250134812-A1 | SYNTHETIC GLYCOLIPIDS AND GLYCOLIPOSOME COMPOSITIONS : SUITABLE FOR CARGO DELIVERY TO THE CENTRAL NERVOUS SYSTEM | KORANEX CAPITAL (CA) | 2025-05-01 | — | — | US | disclosed |
| US-20220380763-A1 | NUCLEIC ACID DELIVERY ENHANCER | NATIONAL UNIVERSITY CORPORATION KOCHI UNIVERSITY (JP) | 2022-12-01 | — | — | US | disclosed |
| EP-4049664-A1 | NUCLEIC ACID DELIVERY ENHANCER | National University Corporation Kochi University (JP) | 2022-08-31 | — | — | EP | disclosed |
| US-20220233673-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2022-07-28 | — | — | US | disclosed |
| EP-3999094-A1 | A UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-TARGETING PEPTIDE | Rigshospitalet (DK) | 2022-05-25 | — | — | EP | disclosed |
| WO-2022049604-A1 | PROCESS FOR PREPARING REVEFENACIN AND INTERMEDIATES THEROF | CIPLA LIMITED (IN) | 2022-03-10 | — | — | WO | disclosed |
| WO-2022040473-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2022-02-24 | — | — | WO | disclosed |
| US-20190194246-A1 | SOLID PHASE PEPTIDE SYNTHESIS | CEM CORPORATION (US) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360147-A1 | Process for Synthesizing Naphthyridine Derivatives and Intermediates Thereof | NME1, NPM1, NME2 | DGAT1 2387/4885KMT2A 2878/4885MAPT 3408/4885 |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | STXBP1, RNGTT, UPF1 | DGAT1 3742/4885KMT2A 1584/4885MAPT 2925/4885 |
| US-12577236-B2 | Processes for preparation of Tezacaftor | CYP4A11, F9, CYP3A4 | DGAT1 2456/4885KMT2A 398/4885MAPT 3497/4885 |
| US-20220380763-A1 | NUCLEIC ACID DELIVERY ENHANCER | NXF1, WASF2, NUTF2 | DGAT1 2828/4885KMT2A 2709/4885MAPT 4484/4885 |
| US-12297226-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, ACE | DGAT1 2298/4885KMT2A 3890/4885MAPT 876/4885 |
| US-20250134812-A1 | SYNTHETIC GLYCOLIPIDS AND GLYCOLIPOSOME COMPOSITIONS : SUITABLE FOR CARGO DELIVERY TO THE CENTRAL NERVOUS SYSTEM | SGMS2, SGMS1, GBA2 | DGAT1 784/4885KMT2A 1936/4885MAPT 671/4885 |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | STXBP1, HBB, UPF1 | DGAT1 3071/4885KMT2A 1769/4885MAPT 3405/4885 |
| US-12365649-B2 | Process for the preparation of brivaracetam | CYP2C19, CYP2B6, POR | DGAT1 3271/4885KMT2A 1272/4885MAPT 3452/4885 |
| US-20250368657-A1 | METHODS FOR INHIBITING FASCIN | FSCN1, NLN, TNNI3 | DGAT1 1790/4885KMT2A 4603/4885MAPT 1238/4885 |
| US-20190194246-A1 | SOLID PHASE PEPTIDE SYNTHESIS | VIP, SPPL2B, PTMS | DGAT1 4368/4885KMT2A 4327/4885MAPT 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.